Ludwig Institute for Cancer Research Limited

Basf Aktiengesellschaft

Solco Basel Ag

Sloan-kettering Institute for Cancer Research

Oxford University Innovation Ltd

The University of Birmingham

Other

Merck Patent Gesellschaft MIT Beschrankter Haftung

The Chancellor, Masters and Scholars of the University of Oxford

Richard R Schmidt

Gerd J Ritter

Gurdyal S Besra

Vincenzo Cerundolo

Gopal Reddy

Rengarajan Balamurugan

Mariolina Salio

Jonathan Silk

Lloyd J Old

Alfred Oftring

Gerhard Wolf

Peter Smith-Jones

Enver Arslantas

Wolfgang Klotz

Peter Zimmermann

Julio C Castro-Palomino

Guenter Oetter

Jurgen Hemberger

Albrecht Wendel

Beate Strecker

Willy Kinzy

Wolfgang Fraefel

Roland Tschannen

Rolf Nuck

Werner Reutter

Andreas Doll

Hendrik Wulff

Martin Maier

Barbara Spahngehl

Karl-Heinz Jung

Rudolf Klager

Andreas Terjung

Karin Jankowski

Peter Zimmerman

Thomas Baer

J&ouml;rg Rademann

Charlotte Hauser

Martin Gohlke

Rudolf Tauber

Sabine N&ouml;hring

R&uuml;diger Horstkorte

Gurdyal Besra

Analogs of alpha galactosylceramide and uses thereof

New bifunctional chelation complexes are described. These are based on the structure of the so-called 'TAME-HexA' molecule. The compounds are especially useful for forming chelation complexes with metal ions, including radioisotopes.

Tame based chelators and uses thereof

There are disclosed compound of formula I, in which Rrepresents a hydrophobic moiety adapted to occupy the C' channel of human CDId, Rrepresents a hydrophobic moiety adapted to occupy the A&#x2032; channel of human CDId, such that Rfills at least at least 30% of the occupied volume of the C&#x2032; channel compared to the volume occupied by the terminal nCHof the sphingosine chain of &#x3b1;-galactosylceramide when bound to human CDId and Rfills at least 30% of the occupied volume of the A&#x2032; channel compared to the volume occupied by the terminal nCHof the acyl chain of &#x3b1;-galactosylceramide when bound to human CDId Rrepresents hydrogen or OH, Rand Reach represent hydrogen and in addition, when Rrepresents hydrogen, Rand Rtogether may form a single bond, X represents or &#x2014;CHA(CHOH)Y or &#x2014;P(=0)(0)0CH(CH0H)Y, in which Y represents CHBB, n represents an integer from 1 to 4, m represents 0 or 1, A &#xe5;represents hydrogen, one of Band Brepresents H, OH or phenyl, and the other represents hydrogen or one of Band Brepresents hydroxyl and the other represents phenyl, in addition, when n represents 4, then A together with one of Band Btogether forms a single bond and the other of Band Brepresents H, OH or OSOH and pharmaceutically acceptable salts thereof; the compounds of formula I are indicted for use in the treatment of a virus, microbial infection, parasite, an autoimmune disease, cancer, allergy or asthma. 

Analogs of alpha galactosyceramide and uses thereof

The invention relates to novel recombinant glycoproteins that act as messenger substances, signaling substances, promoters, stimulators and initiators in a multitude of ways in the animal, especially human, circulation system. The invention also relates to a method for the production thereof, pharmaceutical agents containing said glycoproteins and the use thereof The invention more particularly relates to novel recombinant human glycoproteins (rh glycoproteins), preferably novel rh differentiation factors, especially rh erythropoietin; novel rh growth factors, especially rh CSF (colony stimulating factor), rh GMCSF (granulocytes monocytes stimulation factor); novel rh thrombolytic agents, especially rh tPA (tissue plasminogen activator) and rh urokinase; novel rh thromboprophylactic agents, especially rh antithrombin III; novel rh coagulation factors, especially rh factor VIII and rh factor IX; novel rh interferons, especially rh &agr;, &bgr; and &ggr; interferons; and novel rh interleukins, especially rh IL-2, IL-15, IL-16 and IL-17. The invention further relates to a method for the production of said substances, pharmaceutical agents containing them and to the use thereof.

Recombinant glycoproteins, method for the production thereof, medicaments containing said glycoproteins and use thereof

The invention relates to carbohydrate derivatives, to a process for their preparation and to their use.

Carbohydrate derivatives and their solid-phase synthesis

The invention describes an improved method for making monosialoganglioside GM3 and its intermediates. Following reaction of a neuraminic acid donor and a lactose acceptor in the presence of an acid catalyst, the .alpha. and .beta. isomers of GM3 are formed. The .alpha. isomer is converted to a lactone, via action of a ring forming basic catalyst, which is then separable from the .beta. isomer. The lactone is then treated with a basic catalyst in the presence of an alcohol, to form GM3 or a GM3 intermediate.

Methods of synthesizing GM3

This invention relates to methods of producing synthetic GM2s. The methods are simple and efficient, and result in high yields of GM2s.

Methods of synthesizing GM2

1-(2'-hydroxy and 2'-sulfatoalkyl) glycoside

Preparation of alkyl glycosides

The invention relates to a process for the stereoselective preparation of .beta.-L-fucopyranosyl phosphates via the trichloroacetimidates of protected L-fucose and the synthesis and purification of very pure GDP-fucose from the .beta.-L-fucopyranosyl phosphates.

Process for the stereoselective preparation of .beta.-fucopyranosyl

Bisglycosides

The compounds of the formula I exert a pronounced specific cytoprotective effect; they can be used for the treatment of acute and chronic inflammations and organ ischemias caused by narrowing of vessels. R.sup.1 denotes an aliphatic radical having 9 to 19 C atoms in the straight chain, R.sup.2 denotes the acyl radical of a saturated or unsaturated fatty acid having 14 to 24 C atoms, and X denotes a --CH.sub.2 CH.sub.2 --or --CH.dbd.CH-- group. The invention relates to pharmaceutical products in which the active ingredient is the said compounds, as well as to those compounds I in which R.sup.2 denotes the acyl radical of an unsaturated fatty acid, and to the process for the preparation thereof. ##STR1##

Pharmaceutical products and lactosyl compounds

New compounds of the formula (I)-D and (I)-L as shown in the sheet of formulae are described, for example D- and L-erythro-1-(.beta.-D-glycopyranosyloxy)-3-hydroxy-2-palmitoylamino-4-tran s-octadecene, which exert actions promoting wound healing and cell and tissue regeneration, and can be used therapeutically for the treatment of wounds of any cause. They are prepared in good yield and in a stereochemically homogeneous form from ceramides of the formula (II)-D and/or (II)-L. The process comprises the protection of the 1-hydroxyl group, esterification of the 3-hydroxyl group, elimination of the 1-hydroxyl protective group, reaction with the trifluoroacetimidate or trichloroacetimidate of a 2,3,4,6-tetraacylated D-glucose and elimination of the O-acyl groups. When a D,L-ceramide (II) is used, the esterification of the 3-hydroxyl group is carried out by an optically active acid followed by separation into the diastereomers, or separation into the diastereomers is carried out after the reaction with the D-glucose derivative.

Process for the preparation of sphingosine derivatives

Growing community of inventors

Constance, Germany

Richard R Schmidt